paroxetine has been researched along with Colonic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, WJ; Jeong, CH; Jung, SK; Vo, TTL | 1 |
| Bar, M; Gil-Ad, I; Lomnitski, L; Luria, D; Ram, E; Taler, M; Weizman, A; Zolokov, A | 1 |
2 other study(ies) available for paroxetine and Colonic Neoplasms
| Article | Year |
|---|---|
Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; HCT116 Cells; HT29 Cells; Humans; Male; Mice; Mice, Nude; Paroxetine; Proto-Oncogene Proteins c-met; Receptor, ErbB-3; Selective Serotonin Reuptake Inhibitors | 2019 |
Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice.
Topics: Adenocarcinoma; Animals; Antidepressive Agents; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Paroxetine; Sertraline; Xenograft Model Antitumor Assays | 2008 |